Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents: appropriate use of animal models
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Washington D.C.
National Academies Press
c2006
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Includes bibliographical references Selection or development of an animal model -- Generation and characterization of aerosolized agents -- Dosimetry considerations -- Experimental design -- Resource issues The National Institute of Allergy and Infectious Diseases (NIAID) gives the highest priority to developing countermeasures against bioterrorism agents that are highly infective when dispersed in aerosol form. Developing drugs to prevent or treat illnesses caused by bioterrorism agents requires testing their effectiveness in animals since human clinical trials would be unethical. At the request of NIAID, the National Academies conducted a study to examine how such testing could be improved. Overcoming Challenges to Develop Countermeasures Against Aerosolized Bioterrorism Agents provides recommendations to researchers on selecting the kinds of animal models, aerosol generators, and bioterrorism agent doses that would produce conditions that most closely mimic the disease process in humans. It also urges researchers to fully document experimental parameters in the literature so that studies can be reproduced and compared. The book recommends that all unclassified data on bioterrorism agent studies -- including unclassified, unpublished data from U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) -- be published in the open literature. The book also calls on the U.S. Food and Drug Administration to improve the process by which bioterrorism countermeasures are approved based on the results of animal studies |
| Beschreibung: | 1 Online-Ressource (xvi, 71 p.) |
| ISBN: | 0309660939 9780309660938 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043068574 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2006 |||| o||u| ||||||eng d | ||
| 020 | |a 0309660939 |c electronic bk. |9 0-309-66093-9 | ||
| 020 | |a 9780309660938 |c electronic bk. |9 978-0-309-66093-8 | ||
| 035 | |a (OCoLC)290496648 | ||
| 035 | |a (DE-599)BVBBV043068574 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 615.9 |2 22 | |
| 245 | 1 | 0 | |a Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents |b appropriate use of animal models |c Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents, Board on Life Sciences, Institute for Laboratory Animal Research, Division of Earth and Life Studies |
| 264 | 1 | |a Washington D.C. |b National Academies Press |c c2006 | |
| 300 | |a 1 Online-Ressource (xvi, 71 p.) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references | ||
| 500 | |a Selection or development of an animal model -- Generation and characterization of aerosolized agents -- Dosimetry considerations -- Experimental design -- Resource issues | ||
| 500 | |a The National Institute of Allergy and Infectious Diseases (NIAID) gives the highest priority to developing countermeasures against bioterrorism agents that are highly infective when dispersed in aerosol form. Developing drugs to prevent or treat illnesses caused by bioterrorism agents requires testing their effectiveness in animals since human clinical trials would be unethical. At the request of NIAID, the National Academies conducted a study to examine how such testing could be improved. Overcoming Challenges to Develop Countermeasures Against Aerosolized Bioterrorism Agents provides recommendations to researchers on selecting the kinds of animal models, aerosol generators, and bioterrorism agent doses that would produce conditions that most closely mimic the disease process in humans. It also urges researchers to fully document experimental parameters in the literature so that studies can be reproduced and compared. The book recommends that all unclassified data on bioterrorism agent studies -- including unclassified, unpublished data from U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) -- be published in the open literature. The book also calls on the U.S. Food and Drug Administration to improve the process by which bioterrorism countermeasures are approved based on the results of animal studies | ||
| 650 | 7 | |a MEDICAL / Toxicology |2 bisacsh | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Bioterrorism |x Research | |
| 650 | 4 | |a Chemical warfare | |
| 650 | 4 | |a Toxicity testing | |
| 650 | 4 | |a Toxicology | |
| 650 | 4 | |a Toxicology |x Animal models | |
| 710 | 2 | |a National Research Council (U.S.) |b Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents |e Sonstige |4 oth | |
| 710 | 2 | |a National Research Council (U.S.) |b Board on Life Sciences |e Sonstige |4 oth | |
| 710 | 2 | |a Institute for Laboratory Animal Research (U.S.) |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Paperback |z 0-309-10211-1 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Paperback |z 978-0-309-10211-7 |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=170122 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028492766 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=170122 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=170122 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175449771737088 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043068574 |
| collection | ZDB-4-EBA |
| ctrlnum | (OCoLC)290496648 (DE-599)BVBBV043068574 |
| dewey-full | 615.9 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.9 |
| dewey-search | 615.9 |
| dewey-sort | 3615.9 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03874nmm a2200493zc 4500</leader><controlfield tag="001">BV043068574</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2006 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309660939</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-309-66093-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309660938</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-309-66093-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)290496648</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043068574</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.9</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents</subfield><subfield code="b">appropriate use of animal models</subfield><subfield code="c">Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents, Board on Life Sciences, Institute for Laboratory Animal Research, Division of Earth and Life Studies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington D.C.</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">c2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xvi, 71 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Selection or development of an animal model -- Generation and characterization of aerosolized agents -- Dosimetry considerations -- Experimental design -- Resource issues</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">The National Institute of Allergy and Infectious Diseases (NIAID) gives the highest priority to developing countermeasures against bioterrorism agents that are highly infective when dispersed in aerosol form. Developing drugs to prevent or treat illnesses caused by bioterrorism agents requires testing their effectiveness in animals since human clinical trials would be unethical. At the request of NIAID, the National Academies conducted a study to examine how such testing could be improved. Overcoming Challenges to Develop Countermeasures Against Aerosolized Bioterrorism Agents provides recommendations to researchers on selecting the kinds of animal models, aerosol generators, and bioterrorism agent doses that would produce conditions that most closely mimic the disease process in humans. It also urges researchers to fully document experimental parameters in the literature so that studies can be reproduced and compared. The book recommends that all unclassified data on bioterrorism agent studies -- including unclassified, unpublished data from U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) -- be published in the open literature. The book also calls on the U.S. Food and Drug Administration to improve the process by which bioterrorism countermeasures are approved based on the results of animal studies</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Toxicology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bioterrorism</subfield><subfield code="x">Research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemical warfare</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicity testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield><subfield code="x">Animal models</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">National Research Council (U.S.)</subfield><subfield code="b">Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">National Research Council (U.S.)</subfield><subfield code="b">Board on Life Sciences</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute for Laboratory Animal Research (U.S.)</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Paperback</subfield><subfield code="z">0-309-10211-1</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Paperback</subfield><subfield code="z">978-0-309-10211-7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=170122</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028492766</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=170122</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=170122</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043068574 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:16:28Z |
| institution | BVB |
| isbn | 0309660939 9780309660938 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028492766 |
| oclc_num | 290496648 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 Online-Ressource (xvi, 71 p.) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents, Board on Life Sciences, Institute for Laboratory Animal Research, Division of Earth and Life Studies Washington D.C. National Academies Press c2006 1 Online-Ressource (xvi, 71 p.) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references Selection or development of an animal model -- Generation and characterization of aerosolized agents -- Dosimetry considerations -- Experimental design -- Resource issues The National Institute of Allergy and Infectious Diseases (NIAID) gives the highest priority to developing countermeasures against bioterrorism agents that are highly infective when dispersed in aerosol form. Developing drugs to prevent or treat illnesses caused by bioterrorism agents requires testing their effectiveness in animals since human clinical trials would be unethical. At the request of NIAID, the National Academies conducted a study to examine how such testing could be improved. Overcoming Challenges to Develop Countermeasures Against Aerosolized Bioterrorism Agents provides recommendations to researchers on selecting the kinds of animal models, aerosol generators, and bioterrorism agent doses that would produce conditions that most closely mimic the disease process in humans. It also urges researchers to fully document experimental parameters in the literature so that studies can be reproduced and compared. The book recommends that all unclassified data on bioterrorism agent studies -- including unclassified, unpublished data from U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) -- be published in the open literature. The book also calls on the U.S. Food and Drug Administration to improve the process by which bioterrorism countermeasures are approved based on the results of animal studies MEDICAL / Toxicology bisacsh Medizin Bioterrorism Research Chemical warfare Toxicity testing Toxicology Toxicology Animal models National Research Council (U.S.) Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents Sonstige oth National Research Council (U.S.) Board on Life Sciences Sonstige oth Institute for Laboratory Animal Research (U.S.) Sonstige oth Erscheint auch als Druck-Ausgabe, Paperback 0-309-10211-1 Erscheint auch als Druck-Ausgabe, Paperback 978-0-309-10211-7 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=170122 Aggregator Volltext |
| spellingShingle | Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models MEDICAL / Toxicology bisacsh Medizin Bioterrorism Research Chemical warfare Toxicity testing Toxicology Toxicology Animal models |
| title | Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models |
| title_auth | Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models |
| title_exact_search | Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models |
| title_full | Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents, Board on Life Sciences, Institute for Laboratory Animal Research, Division of Earth and Life Studies |
| title_fullStr | Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents, Board on Life Sciences, Institute for Laboratory Animal Research, Division of Earth and Life Studies |
| title_full_unstemmed | Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents, Board on Life Sciences, Institute for Laboratory Animal Research, Division of Earth and Life Studies |
| title_short | Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents |
| title_sort | overcoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models |
| title_sub | appropriate use of animal models |
| topic | MEDICAL / Toxicology bisacsh Medizin Bioterrorism Research Chemical warfare Toxicity testing Toxicology Toxicology Animal models |
| topic_facet | MEDICAL / Toxicology Medizin Bioterrorism Research Chemical warfare Toxicity testing Toxicology Toxicology Animal models |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=170122 |
| work_keys_str_mv | AT nationalresearchcounciluscommitteeonanimalmodelsfortestinginterventionsagainstaerosolizedbioterrorismagents overcomingchallengestodevelopcountermeasuresagainstaerosolizedbioterrorismagentsappropriateuseofanimalmodels AT nationalresearchcouncilusboardonlifesciences overcomingchallengestodevelopcountermeasuresagainstaerosolizedbioterrorismagentsappropriateuseofanimalmodels AT instituteforlaboratoryanimalresearchus overcomingchallengestodevelopcountermeasuresagainstaerosolizedbioterrorismagentsappropriateuseofanimalmodels |